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“Vulvar dystrophy” is characterized by chronic alterations of vulvar trophism, occurring in both physiological (menopause) and
pathological (lichen sclerosus, vulvar graft-versus-host disease) conditions. Associated symptoms are itching, burning, dyspareunia
and vaginal dryness. Current treatments often do not imply a complete remission of symptoms. Adipose-Derived Stem Cells
(ADSCs) injection represents a valid alternative therapy to enhance trophism and tone of dystrophic tissues. We evaluated efficacy
of ADSCs-based therapy in the dystrophic areas. FromFebruary toApril 2013 we enrolled 8 patients with vulvar dystrophy. A biopsy
specimen was performed before and after treatment. Digital photographs were taken at baseline and during the follow-up. Pain was
detected with Visual Analogue Scale and sexual function was evaluated with Female Sexual Function Index. All patients received
2 treatments in 3 months. Follow-up was at 1 week , 1 and 3 months, and 1 and 2 years. We obtained a significant vulvar trophism
enhancement in all patients, who reported pain reduction and sexual function improvement. Objective exam with speculum was
easy to perform after treatment. We believe ADSCs-based therapy finds its application in the treatment of vulvar dystrophies, since
ADSCs could induce increased vascularization due to their angiogenic properties and tissue trophism improvement thanks to their
eutrophic effect.
1. Introduction
Vulvar dystrophy is a condition which may occur in women
both in physiological and in pathological conditions. Asso-
ciated symptoms may include itching, burning, dyspareunia,
vaginal dryness and bleeding. Vaginal dystrophy commonly
affects postmenopausal women, with prevalence ranging
from 10% to 50% [1, 2] and it is estimated that up to 45% of all
women are symptomatic [3]. The aetiology of vulvovaginal
atrophy among postmenopausal women is most commonly
explained by the decrease in circulating estrogen associated
with the menopausal transition, which has an adverse effect
on skin collagen and elasticity [4]. Evenwhile taking systemic
estrogen, 10% to 20% of women may still have residual
symptoms [5]. Symptoms related to estrogen reduction may
also occur during other stages of women’s lives in response to
events associated with sustained decreases in estrogen such
as lactation or also related to chemotherapy that induces
premature ovarian failure in 14–100% of cases. These patients
are at high risk of transient or permanent amenorrhea, and,
for those women who continue to menstruate or who recover
their cycles, there is an additional long-term risk of prema-
ture ovarian failure. In particular, breast cancer treatment
increases the prevalence of vulvar dystrophy because the
surgical, endocrine, and chemotherapeutic agents used in
its treatment can cause or exacerbate this condition. An
iatrogenic cause of vulvar dystrophy is related to allogeneic
hematopoietic stem cell transplant.This procedure has found
a place in the treatment of a variety of malignant and
nonmalignant diseases of the bone marrow and immune
system. However, it may be complicated by chronic graft-
versus-host disease (GVHD), due to activation of donor
immunological cells against host tissues. GVHD may occur
in acute or chronic forms. The skin, mouth, eyes, liver,
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and intestines are the organs most commonly involved in
chronicGVHD.Genital tract involvement can occur in nearly
25% of patients with GVHD. Vulvar scarring can lead to
vaginal stenosis and introital reduction and may also result
in labial fusion [6]. These manifestations can lead to some
complications as hematometra, hematocolpos, and abscesses.
Hypoestrogenism from chemotherapy-induced premature
ovarian failure and chronic GVHD can both cause vulvar or
vaginal pain and irritation. Lichen sclerosus (LS) is a chronic
immune-mediated inflammatory skin disorder of poorly
understood aetiology [7, 8], whichmay be localized anywhere
on the body but has a predilection for the anogenital area [9].
Although disease onset has been reported at all ages, it occurs
most commonly inwomen in their fifth or sixth decade of life.
Skin changes of the vulva initially begin with white, polyg-
onal papules that coalesce into plaques, with skin atrophy
and perifocal erythema. Additionally, subcutaneous bleeding
with ecchymosis or hematosis and fissures with superficial
ulceration and erosionmay occur. Late progressive symptoms
include thinning of the mucosa, edema and fibrosis of the
dermis, shrinkage of the labia, and agglutination of the labia
minora that can lead to stenosis of the introitus. Moreover,
while the disorder is considered benign, some women with
vulvar LS may later develop squamous cell carcinoma (SCC)
of the vulva and some women have concomitant SCC when
initially diagnosed with LS [10]. Vulvar dystrophy may
negatively affect the entire sexual response cycle, inducing
significant changes in desire, arousal, orgasm, and satisfaction
at menopause and beyond. Patients may be embarrassed by
the disfiguring changes that may occur and avoid sexual
intimacy. Furthermore these patientsmay have increased risk
to develop bacterial vaginosis due to vaginal pH changes
and urinary tract infection or stress urinary incontinence.
Main treatments to solve urogenital and sexual dysfunction
due to vulvovaginal tissue alteration currently include drug
therapy and lubricants, but in the majority of patients these
therapies do not imply a complete remission of symptoms.
Recent studies emphasized that adipose tissue is a rich source
of adult stem cells, the so-called Adipose-Derived Stem Cells
(ADSCs) [11–13]. We tested the hypothesis that the vulvar
application of ADSCs can enhance the trophism and tone of
dystrophic tissues.
2. Materials and Methods
2.1. Patients. The clinical trial protocol, conformed to
the guidelines of the Declaration of Helsinki (1964), was
approved by the Ethical Committee of our institution
(Ref.1834/25.03.10). From February to April 2013 we enrolled
8 patients affected with vulvar dystrophy of average age
of 56.5 (between 38 and 75 years old). Among them, one
patient was in postmenopause, 2 women were affected with
vulvar GVHD, and 5 were affected with LS. At each visit,
personal, anamnestic, and objective data were collected. Our
study was conducted with the patients’ understanding and
consent. Patients were informed of the purpose and objective
of the investigation andwere asked for their written informed
consent for participation and publication of the data obtained
during the course of the study. Inclusion criteria called for
vulvar dystrophy’s symptoms and signs, patients’ refusal of
lipofilling, and patients nonresponders to traditional therapy.
Exclusion criteria were pregnancy or lactation and associated
pathologies contraindicating the proposed treatment.
All patients received 2 treatments in 3 months. Follow-up
was at 1 week and 1 and 3 months and at 1 and 2 years.
2.2. Surgical Techniques. The adipose tissue collection was
performed through liposuction from the abdominal region
or trochanteric areas, depending on the easier access to a suf-
ficient amount of adipose tissue.The samplingwas carried out
under local anesthesia, using amodifiedKlein solution (1 liter
of sodium chloride 0.9%, 20mL of lidocaine 2%, and 1mL of
epinephrine 1 : 200,000) through a single hole of 3mm blunt
cannula connected to a 10 cc Luer-lock syringe.The harvested
fat was centrifuged at 1500 rpm for 2 minutes. After centrifu-
gation, the oil layer (upper level) and the aqueous layer (lower
level) were eliminated from the syringe. The middle layer
containing adipocytes and stromal vascular component was
sent to the laboratory for cell cultivation within 1 hour.
2.3. Cell Isolation and Culture. The fat was transferred into
a sterile tube and washed extensively with sterile phosphate-
buffered saline (PBS) containing 2% PSG to remove contam-
inating debris and red blood cells. The stromal vascular frac-
tion (SVF), containing the ADSCs, was then pelleted by cen-
trifugation for 5min at 2000 rpm [14] and then resuspended
in DMEM-Ham’s F-12 medium (vol/vol, 1 : 1) (DMEM/F-12,
Gibco) supplemented with 20% FBS, 100U/mL penicillin,
100 𝜇g/mL streptomycin, and 2mM L-glutamine and plated
in a 75 cm2 tissue culture flask coated with collagen type IV.
ADSCs were self-selected out of the SVF during subse-
quent tissue culture passages, on the basis of their ability to
adhere to the plastic tissue cultureware, and maintained in
a 5% CO
2
incubator at 37∘C in a humidified atmosphere,
with medium change twice a week. Cell viability was assessed
by using the trypan blue exclusion assay. A homogeneous
population of ADSCs was subsequently checked by deter-
mining growth kinetics and by analyzing the surface-marker
expression profile.
2.4. Preparation of Cell-Enriched Hyaluronic Acid. Primary
cultures of ADSCs derived from each patient were expanded
in order to obtain an adequate number of 75 cm2 flasks at 95–
100% confluence. Once the appropriate number of cells was
reached for each patient, cells were detached with 0.5mM
EDTA/0.05% trypsin for 5min at 37∘C and counted. Then,
ADSCs were centrifuged at 1500 rpm for 10 minutes, washed
twice in phosphate-buffered saline to remove serum, and
resuspended in an adequate volume of synthetic stabilized
low molecular weight hyaluronic acid solution (a 1.6% solu-
tion of synthetic HA, without chemical modifications and
with a molecular weight of 1 × 103 KDa, very similar to
the endogenous HA) at the standard concentration of 5 ×
105 cells/mL, to vehicle stem cells and to facilitate subsequent
infiltration. After mixing, the suspension was kept under
ambient conditions for 10 to 15 minutes to allow cell adher-
ence to the hyaluronan matrix. Homogeneous dispersion
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of the cells within the gel was ensured by microscopical
observation. Then, the cell-supplemented hyaluronic acid
solution was loaded into an injection syringe and carried to
the operating room.
2.5. ADSCs Infiltration. Usually after 3 weeks, the patient
went back to the operating room for the inoculation of autol-
ogous ADSCs into the dystrophic areas. The procedure was
performed in local anesthesia with sedation, with the patient
in the dorsal lithotomy. The infiltration was done using two
2mL syringes provided with a 30-gauge 1/2 needle by means
of multiple passes in the subcutaneous plane of labia minora.
We employed 2mL of hyaluronic acid for each patient, keep-
ing a constant rate of 5 × 105 cells for each mL of hyaluronic
acid. All patients were dismissed the following day.
2.6. Clinical Evaluation. The evaluated parameters were tis-
sue trophism, pain, and sexual satisfaction. Tissue trophism
was evaluated by photographic documentation and biopsy
performed before and after treatment. Photographs were
taken in occasion of follow-up utilizing the same parameters
(same camera Canon EOS 500D, same shooting distance of
50 cm, and same anatomical landmarks). Pain was estimated
at T0 and weekly according to the Visual Analogue Scale
(VAS). A range from 1 (no pain) to 10 (maximal sensation
of pain) was considered. Sexual function was assessed by the
Female Sexual Function Index (FSFI), performed before and
after treatment. It consists of 19 questions on the sexual activ-
ity performed in the last four weeks. It enables assessment of
six sexual functioning domains: desire, arousal, lubrication,
orgasm, satisfaction, and discomfort/pain [15]. Subdomains
are scored considering the values of each question and its
respective conversion factors, and total FSFI Score was calcu-
lated as the sum of the six results, ranging from 2 to 36. Better
levels of sexual function were indicated by highest scores.
3. Results
All patients were followed postoperatively at least for 2
years, with periodical medical assessments at 1 week, 1 and
3 months, and 1 and 2 years.
Just one month after the first ADSCs infiltration,
improvement of vulvar trophism was clinically observed,
enhancing progressively over time. Pain reduction was
already documented at one month after the first treatment;
dramatic pain reduction was obtained after 1 year. Sexual
function improved significantly at onemonth after the second
treatment. Overall results in terms of pain reduction, vul-
var trophism, and sexual function improvement were well-
maintained at 2 years’ follow-up. In particular, photographic
documentation at 2 years’ follow-up revealed an improve-
ment of vulvar trophism, showing a pink vulvar skin color, a
restoration of elasticity, and the disappearing of erythematous
areas.We observed that speculumexamwas easier to perform
and painless as indicated from the patients. A loss of vaginal
rugae, vaginal pallor, and petechiae was evident in the patient
affected in menopause. Histological exam in menopause
patient demonstrated improvement of the elastic network.
Figure 1: Before ADSCs.
Figure 2: After ADSCs.
In patients with LS, showing extensive erythema of the labia
minora extending onto the interlabial sulci (which also show
lichenification) and the vaginal introitus before treatment
(Figure 1), we observed that erythema was dramatically
reduced and disappeared at level of the interlabial sulci
and the vaginal introitus after ADSCs infiltration (Figure 2).
In patients affected with GVHD, histological examination
documented apoptotic cells in the basal layer, epithelial
detachment from the thinning mucosa, collagen hyalinosis,
and monocytic infiltrate in the submucosa. After treatment
with ADSCs, a regression of the morphological alterations
of epithelial cells and full attenuation of inflammatory signs
in the connectival tissue were observed. Biopsy specimens
of patients affected with LS displayed epithelial acanthosis,
appendageal hyperkeratosis and dermal modifications with
hyalinization, lymphocytic infiltrate with a longitudinal band
in the medium dermis, wide ectatic capillaries, and lympho-
cyte tagging along the basement membrane. After treatment
with ADSCs, the dermis sclerosis was significantly reduced,
capillaries that resulted were less dilated, and inflamma-
tory infiltrate was dramatically reduced (Figures 3 and 4).
According to the VAS, a remarkable pain reduction could be
observed in all patients, as shown in Table 1. Moreover, FSFI
revealed that all patients obtained an improvement of sexual
function after ADSCs treatment, as documented in Table 2.
Our method was efficacious regardless of the aetiology of
vulvar dystrophy.
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Figure 3: Hematoxylin-eosin staining ×10. Epidermis with mild
parakeratotic hyperkeratosis ectatic capillaries, sclerotic dermis, and
inflammatory infiltrate.
Figure 4: Hematoxylin-eosin staining ×10. Reduction of dermis
sclerosis, capillaries less dilatated, inflammatory infiltrate dramat-
ically reduced.
Table 1: Visual Analogue Scale (VAS) score before and after
treatment.
Cases Patients (𝑁) VAS score
Before ADSCs After ADSCs
Menopause 1 7 1
GVHD 1 9 2
1 8 1
LS
1 8 1
1 7 1
1 8 1
1 9 2
1 8 1
4. Discussion
Vulvar dystrophy negatively impacts women’s lives, but
women lack knowledge of the subject and are hesitant
to consult healthcare professionals, who should proactively
initiate discussions regarding appropriate treatment options.
Main treatments to solve urogenital and sexual dysfunction
due to vulvovaginal tissue dystrophy currently include drug
therapies and lubricants but in the majority of patients they
Table 2: Female Sexual Function Index (FSFI) before and after
treatment.
Cases Patients (𝑁) FSFI
Before ADSCs After ADSCs
Menopause 1 10 30
GVHD 1 15 30
1 20 30
LS
1 15 36
1 14 35
1 12 35
1 10 36
1 10 36
do not imply a complete remission of symptoms. Lubricants
can be used to decrease immediate irritation during coital
activity, but there is no evidence that these products have any
long-term therapeutic effect. Systemic hormone replacement
is indicated for women who are seeking to treat a variety
of symptoms associated with the estrogen deprivation of
menopause, such as hot flushes and sleep disturbance, but,
in some women, it is not an effective method for relieving
vulvovaginal atrophy [16]. Furthermore, estrogens cannot
be used in women affected with breast cancer undergoing
the hormone suppressive therapy. To date, new therapeutic
approaches have been experimented. Hyaluronic acid (HA)
infiltration is recently used for vaginal rejuvenation. HA
is an unbranched, nonsulphated polysaccharide, and it is
biocompatible, nontoxic, and biodegradable. Due to its high
water-binding capacity or hygroscopicity, it induces tissue
hydration and lubrication [17]. In the skin, HA is produced
intracellularly at the cell membrane of fibroblasts by HA-
synthases [18] and extruded directly into the extracellular
matrix. Since HA is chemically and structurally identical,
regardless of its origin, allergic reactions are rare and skin
tests before injection are not necessary. This led to the
use of HA in several tissue engineering areas, such as
aesthetic surgery. Moreover, previous observations suggested
that nonanimal stabilized hyaluronic acid may confer filling
effects, attributable to its stimulatory effect on collagen
production [19], but a major drawback of HA is the lack of
a tissue regeneration, with the filling material that is only
degraded and not replaced by autologous tissue. Therefore,
it is almost completely reabsorbed after 1 month, and its
effects are only temporary. In the last few years, autologous
fat transplantation has become the first-choice treatment
to restore volumes and to achieve structural modifications.
This approach, using the patient’s own body fat as a natural
filler, takes advantage of its abundance and accessibility,
thus avoiding complications associatedwith foreignmaterials
[20]. Nevertheless, many studies demonstrated that the most
part of adipose tissue grafts is reabsorbed through time or
replaced by fibrous tissue, and they also display a low rate
of survey due to partial necrosis [21]. Lipofilling benefits
have already been proved in dystrophies and vulvar reju-
venating treatments. As outlined above, the adipose tissue
is a rich source of ADSCs. This stem cell reservoir can be
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easily obtained from a very small amount of liposuction
aspirate (1–5 cc) or from adipose tissue biopsy. Further-
more, ADSCs possess the ability to differentiate into various
cell types, including adipocytes, chondrocytes, osteoblasts,
and myoblasts. Therefore, they may represent a promising
approach to cell-based therapies [11–13]. Besides, it has been
recently demonstrated that ADSCs show angiogenic proper-
ties and could also exert some immunomodulatory activities,
including a suppressive response on collagen-reactive T cells
and the capacity to restore immune tolerance by inhibiting
the inflammatory response in vivo [13]. ADSCs infiltration
finds its application in the treatment of physiological and
pathological vulvovaginal dystrophies, since these cells could
induce increased vascularization, due to their angiogenic
properties, and an improvement of tissue trophism, due to
their eutrophying effect. In particular, in patients affected
with pathological inflammatory dystrophies, a reduction of
the typical pain and burning sensation could be obtained
thanks to the immunomodulatory properties of the ADSCs,
which may act by reducing inflammation that represents
the algogenic stimulus of these pathologies. Therefore, it is
possible to obtain the appropriate number of cells to treat
different pathologies, by means of conveyance with a low
molecular weight hyaluronic acid gel, thus allowing an easy
and nontraumatic infiltration in the affected areas. Nonani-
mal stabilized hyaluronic acid represents an ideal scaffold that
can provide structural support and a favorable environment
for growing cells, and it is a natural component of commonly
used injectable soft-tissue filler [22]. Moreover, a further
advantage of this procedure is the reduction of operating
time and the greater compliance of patients and surgeons in
comparison with the traditional invasive techniques.
5. Conclusion
ADSCs injection represents the evolution of a standardized
therapy, such as conventional lipofilling, and a valid alter-
native method to the injection of hyaluronic acid alone for
biorevitalizing purposes.
On the basis of our experience we advocate that ADSCs
infiltration in dystrophic vulvar areas is a safe method, easier
to be performed with respect to the traditional technique,
noninvasive, and requiring short time. It could represent
a valid therapeutic option when patients refuse or present
conditions contraindicating an invasive procedure. In agree-
ment with the positive results previously achieved with this
technique in pathologies characterized by tissue scleroat-
rophy such as scleroderma [14], we obtained encouraging
results in patients suffering from vulvar dystrophies, even
in the long-term, in terms of cutaneous, subcutaneous, and
mucous trophism improvement. Our patients experienced
a restoration of the anatomy, altered by the pathology, and
could improve their quality of life. ADSCs treatment leads
to the reacquisition of vaginal and periurethral tonicity,
thus solving problems related to the hypotrophic involutive
processes affecting the genitourinary tract. After treatment
our patients performed objective exam, Pap test, and other
gynaecological procedures, without pain.
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